BUSINESS
Indian drug makers see hike in Chinese raw material as an opportunity to produce locally
There are around 7,000 active pharmaceutical ingredient manufacturers in China, catering to around 80 percent of India drug makers’ raw material needs.
BUSINESS
Pharma weekly wrap: Singh bros put blame on former top executive Sunil Godhwani for group's financial woes
Godhwani was leading group's financial services arm Religare Enterprises as MD and CEO, was also in charge of the group's holding company, RHC Holding.
BUSINESS
WHO classifies bedaquiline as priority drug in multi-drug resistant TB treatment
WHO, however, warned that it does not have evidence on the safety and effectiveness of bedaquiline use beyond six months, as it was insufficient for review
BUSINESS
Government to launch Ayushman Bharat with public hospitals only, initially
Insurance companies are hoping to play a larger role in the health insurance scheme from 2019 onwards. Due to the proposed low rates, private hospitals have been reluctant to join
BUSINESS
Ayushman Bharat: States still in wait-and-watch mode
Sources told Moneycontrol that there could be a grand launch in states like Gujarat and Haryana tomorrow.
BUSINESS
Fortis Health posts Rs 52.8 crore Q1 loss; shareholders approve $1.1 bn deal with IHH
The deal now needs a go ahead from Competition Commission of India (CCI) to be consummated.
BUSINESS
No reason for pvt hospitals to sit out of path-breaking govt initiative: Ayushman Bharat CEO
“We want to make sure that rates are high enough so that we can attract the private sector, but at the same time they should not be so high that they make the scheme unsustainable,” Bhushan said.
BUSINESS
California verdict on Monsanto's Roundup could have India implications
The latest annual report of Monsanto’s India unit states that its brand Roundup maintains market leadership with sales of around Rs 185.66 crore, which is 28 percent of its net sales of Rs 667.44 crore in FY18
BUSINESS
In a battle over a Rs 250-cr product, Novartis is unwilling to yield an inch
Novartis' Diclofenac injection 75 mg/1 ml was recently banned at the behest of Indian drug regulator after complaints by a little known Ahmedabad-based company, which had a competing product
BUSINESS
The curious case of Oxytocin retail ban by government
The government said the curbs on oxytocin is to restrict the abuse of the hormonal drug by dairy industry on animals.
BUSINESS
Torrent Pharma Q1 profit drops 13% to Rs 162 cr on higher amortisation, finance costs
Torrent Pharma bought domestic formulation business of Unichem Laboratories Rs 3600 crore in December 2017.
BUSINESS
Healthtech disruption: An AI a day helps the doctor a long way
One area that’s ripe for disruption is diagnostics – as successful diagnosis depends on recognition of patterns, mostly visual. That is where AI has an edge compared to humans.
BUSINESS
Delhi HC asks Singh brothers to personally appear for proceedings in Daiichi case
The summons were issued as the court wasn't satisfied with the information provided by Singh brothers on the status of their assets under possession.
BUSINESS
Ayushman Bharat: Insurance companies left in lurch as states opt for trust-based models
In a trust-based model, each state will form its own trust to manage the scheme and claims will be paid from a corpus created from central and state government contributions
BUSINESS
Piramal Enterprises may consider sale of analytics unit if growth doesn't pick up
Will unlock value if topline and profitability of Decision Resources Group (DRG) doesn't go up significantly, says Ajay Piramal
BUSINESS
Piramal Enterprises June quarter loss at Rs 70 crore, hit by one-time charge on imaging biz sale
Excluding the exceptional item - the June quarter net profit grew 27 percent to Rs. 382 crore, on back of strong growth in its financial services and pharmaceutical businesses.
BUSINESS
Dr Reddy's gets expedited hearing of injunction against its launch of gSuboxone in US
Under the expedited schedule ordered by the US Court of Appeals for the Federal Circuit, arguments will be held during the first week of October
BUSINESS
Pharma this week: No relief! Expert panel recommends continuation of govt ban on 343 FDCs
The panel also pointed out that many of these FDCs were formulated without due diligence and the dosing mismatches could result in toxicity that may adversely impact vital organs like liver
BUSINESS
Biocon Q1 net profit jumps 47% to Rs 120 crore, beats analyst estimates
Total revenue for the quarter under review grew 21 percent to Rs 1,192 crore in the April-June period.
BUSINESS
Dr Reddy's profit grows eight-fold on higher sales in India, US & emerging markets
Revenue during the quarter grew 12 percent to Rs 3,721 crore compared to Rs 3,316 crore in the same quarter last year.
BUSINESS
SRL looks to inject new lease of life into biz, rolls out wellness-themed marketing plan
SRL which contributes about one-fifth of Fortis revenues of Rs 4537 crore in FY18, has been struggling to grow its margins and revenues faced with competition and pricing pressure.
BUSINESS
EXCLUSIVE | Govt commissions study on package rates under Modicare, open to revise rates
Niti Aayog and ICMR are tasked to do undertake a detailed study that aims to examine the cost of each procedure and arrive at a suitable package rate.
BUSINESS
Pharma weekly wrap: Daiichi seeks stay on Fortis-IHH deal, Q1 results
The shareholders of Fortis are scheduled to meet at an extraordinary general meeting in Delhi on August 13 to approve IHH’s offer.
BUSINESS
Exclusive | West Bengal to join Modicare, sign MoU with Centre soon
Unlike most other states who are following a trust based model wherein claims are settled from a corpus created from contributions from central and state governments, West Bengal will run the scheme through insurance model which means the state will buy cover from the insurance company that quotes the lowest premium.
